|
Variable\Group
|
Control Group
|
PCOS Group
|
p
|
|---|
|
Age, year
|
27 (20–33)
|
27.5 (22–33)
|
0.383
|
|
BMI, kg/m2
|
22 (19–28)
|
24.1 (19.6–29.5)
|
0.001*
|
|
Insulin, pg/ml
|
8 (3.38–45.56)
|
18.9 (4.85–48.6)
|
< 0.001*
|
|
Office systolic BP, mmHg
|
110.5 ± 9.5
|
120.5 ± 7.2
|
< 0.001*
|
|
Office diastolic BP, mmHg
|
72.6 ± 6.2
|
73.4 ± 5.4
|
0.478
|
|
HOMA-IR
|
1.75 (0.68–9.54)
|
4.27 (1.04–9.36)
|
< 0.001*
|
|
Creatinine, mg/dl
|
0.7 (0.6–0.9)
|
0.8 (0.6–0.9)
|
0.135
|
|
Total Cholesterol, mg/dl
|
169 ± 24
|
175 ± 23
|
0.224
|
|
Triglyceride, mg/dl
|
123 (81–210)
|
156 (68–247)
|
0.044*
|
|
HDL-C, mg/dl
|
52 (34–65)
|
45.5 (33–66)
|
0.004*
|
|
LDL-C, mg/dl
|
90 ± 30
|
100 ± 20
|
0.044*
|
|
Insulin resistance, n (%)
|
22 (30)
|
29 (76)
|
< 0.001*
|
- BP Blood pressure, BMI Body mass index, HOMA-IR The homeostasis model assessment of insulin resistance, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, PCOS Polycystic ovary syndrome. Age, insulin, HOMA-IR, creatinine, and triglyceride were presented as median (maximum-minimum), total cholesterol, LDL-C, were presented as mean standard ± deviation. * indicated a significant difference between controls and patients with polycystic ovary syndrome
